 COPENHAGEN, Denmark, Aug. 31, 2021 GLOBE NEWSWIRE -- Ascendis Pharma AS Nasdaq: ASND, a biopharmaceutical company that utilizes its innovative TransConTM technologies to potentially create new treatments that make a meaningful difference in patients lives, today announced that it has commenced an underwritten public offering of 400,000,000 of American Depositary Shares ADSs, each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional 60,000,000 of ADSs at the public offering price, less the underwriting commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 